On 10th December, two global biopharmaceutical innovators, Bristol Myers Squibb (BMS) and CSL, announced a partnership to help advance blood health across Europe and globally as part of the Blood and Beyond initiative.

Blood and Beyond is a multi-stakeholder initiative co-funded by BMS and CSL, involving experts from haematology, transfusion medicine, patient blood management, nursing, patient advocacy, health economics and hospital management, with support from policymakers. The aim of the initiative is to raise awareness of the importance of good blood health and of the need to tackle the impact of anaemia on patients, healthcare systems and society. Blood and Beyond aims to help to advance policies and practices that improve patient outcomes by supporting patient centricity in anaemia prevention, diagnosis and management through patient blood management and supporting innovation.​

The initiative’s activities include awareness-raising and education for policymakers and health systems, sharing recommendations to inform policy development​ and fostering stakeholder engagement and collaboration.​

The new partnership bolsters Blood and Beyond’s commitment to promoting better health outcomes for anaemia patients​, more efficient use of healthcare resources​ and implementation of Patient Blood Management by health systems and hospitals across Europe and globally​. The initiative will benefit from the companies’ combined expertise in blood disorders and knowledge of healthcare contexts.